A BILL 
To amend the Controlled Substances Act to make marijuana 
accessible for use by qualified marijuana researchers for 
medical purposes, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medical Marijuana Re-
4
search Act’’. 
5
05:02 Oct 26, 2021
H5657
2 
•HR 5657 IH
SEC. 2. FACILITATING MARIJUANA RESEARCH. 
1
(a) PRODUCTION AND SUPPLY.—The Secretary of 
2
Health and Human Services— 
3
(1) until the date on which the Secretary deter-
4
mines that manufacturers and distributors (other 
5
than the Federal Government) can ensure a suffi-
6
cient supply of marijuana (as defined in section 102 
7
of the Controlled Substances Act (21 U.S.C. 802), 
8
as amended by section 8) intended for research by 
9
qualified marijuana researchers registered pursuant 
10
to paragraph (3) of section 303(f) of the Controlled 
11
Substances Act (21 U.S.C. 823(f)), as added by sec-
12
tion 3, shall— 
13
(A) continue, through grants, contracts, or 
14
cooperative agreements, to produce marijuana 
15
through the National Institute on Drug Abuse 
16
Drug Supply Program; 
17
(B) not later than one year after the date 
18
of enactment of this Act, act jointly with the 
19
Attorney General of the United States to estab-
20
lish and implement a specialized process for 
21
manufacturers 
and 
distributors, 
notwith-
22
standing the registration requirements of sec-
23
tion 303 of such Act (21 U.S.C. 823), to supply 
24
qualified marijuana researchers with marijuana 
25
products— 
26
05:02 Oct 26, 2021
H5657
3 
•HR 5657 IH
(i) available through State-authorized 
1
marijuana programs; and 
2
(ii) consistent with the guidance 
3
issued under subsection (c); and 
4
(C) not later than 60 days after the date 
5
of enactment of this Act, jointly convene with 
6
the Attorney General a meeting to initiate the 
7
development of the specialized process described 
8
in subparagraph (B); and 
9
(2) beyond the date specified in paragraph (1), 
10
may, at the Secretary’s discretion, continue— 
11
(A) through grants, contracts, or coopera-
12
tive agreements, to so produce marijuana; and 
13
(B) to implement such specialized process. 
14
(b) REQUIREMENT TO VERIFY REGISTRATION.—Be-
15
fore supplying marijuana to any person through the Na-
16
tional Institute on Drug Abuse Drug Supply Program or 
17
through implementation of the specialized process estab-
18
lished under subsection (a)(1)(B), the Secretary of Health 
19
and Human Services shall— 
20
(1) require the person to submit documentation 
21
demonstrating that the person is a qualified mari-
22
juana researcher seeking to conduct research pursu-
23
ant to section 303(f)(3) of the Controlled Substances 
24
Act, as added by subsection (d) of this section, or 
25
05:02 Oct 26, 2021
H5657
4 
•HR 5657 IH
a manufacturer duly registered under section 303(l) 
1
of the Controlled Substances Act, as added by sec-
2
tion 3 of this Act; and 
3
(2) not later than 60 days after receipt of such 
4
documentation, review such documentation and 
5
verify that the marijuana will be used for such re-
6
search (and for no other purpose authorized pursu-
7
ant to this Act or the amendments made by this 
8
Act). 
9
(c) GUIDANCE
ON USE
OF STATE-AUTHORIZED 
10
MARIJUANA PROGRAMS.—Not later than 180 days after 
11
the date of the enactment of this Act, the Secretary of 
12
Health and Human Services shall issue guidance related 
13
to marijuana from State-authorized marijuana programs 
14
for research. 
15
(d) RESEARCH.—Section 303(f) of the Controlled 
16
Substances Act (21 U.S.C. 823(f)) is amended— 
17
(1) by redesignating paragraphs (1) through 
18
(5) as subparagraphs (A) through (E), respectively; 
19
(2) by striking ‘‘(f) The Attorney General’’ and 
20
inserting ‘‘(f)(1) The Attorney General’’; 
21
(3) by striking ‘‘Registration applications’’ and 
22
inserting the following: 
23
‘‘(2) Registration applications’’; 
24
05:02 Oct 26, 2021
H5657
5 
•HR 5657 IH
(4) in paragraph (2), as so designated, by strik-
1
ing ‘‘schedule I’’ each place that term appears and 
2
inserting ‘‘schedule I, except marijuana,’’; 
3
(5) by striking ‘‘Article 7’’ and inserting the 
4
following: 
5
‘‘(4) Article 7’’; and 
6
(6) by inserting before paragraph (4), as so 
7
designated, the following: 
8
‘‘(3)(A) The Attorney General shall register the ap-
9
plicant to conduct research with marijuana if— 
10
‘‘(i) the applicant is authorized to dispense, or 
11
conduct research with respect to, controlled sub-
12
stances in schedule I, II, III, IV, or V; 
13
‘‘(ii) the applicant is compliant with, and au-
14
thorized to conduct the activities described in clause 
15
(i) under, the laws of the State in which the appli-
16
cant practices; and 
17
‘‘(iii) in the case of an applicant pursuing clin-
18
ical research, the applicant’s clinical research pro-
19
tocol has been reviewed and authorized to proceed by 
20
the Secretary under section 505(i) of the Federal 
21
Food, Drug, and Cosmetic Act. 
22
‘‘(B) An applicant registered under subparagraph (A) 
23
shall be referred to in this section as a ‘qualified mari-
24
juana researcher’. 
25
05:02 Oct 26, 2021
H5657
6 
•HR 5657 IH
‘‘(C)(i) Not later than 60 days after the date on 
1
which the Attorney General receives a complete applica-
2
tion for registration under this paragraph, the Attorney 
3
General shall approve or deny the application. 
4
‘‘(ii) For purposes of clause (i), an application shall 
5
be deemed complete when the applicant has submitted 
6
documentation showing that the requirements under sub-
7
paragraph (A) are satisfied. 
8
‘‘(iii) In the case of a denial under clause (i), the At-
9
torney General shall provide a written explanation of the 
10
basis for the denial. 
11
‘‘(D) The Attorney General shall grant an application 
12
for registration under this paragraph unless the Attorney 
13
General determines that the issuance of the registration 
14
would be inconsistent with the public interest. In deter-
15
mining the public interest, the following factors shall be 
16
considered: 
17
‘‘(i) The applicant’s experience in dispensing, or 
18
conducting research with respect to, controlled sub-
19
stances. 
20
‘‘(ii) The applicant’s conviction record under 
21
Federal or State laws relating to the manufacture, 
22
distribution, or dispensing of controlled substances. 
23
05:02 Oct 26, 2021
H5657
7 
•HR 5657 IH
‘‘(iii) Compliance with applicable State or local 
1
laws relating to controlled substance misuse or diver-
2
sion. 
3
‘‘(iv) Such other conduct which may threaten 
4
the public health and safety. 
5
‘‘(E)(i) A qualified marijuana researcher shall store 
6
marijuana to be used in research in a securely locked, sub-
7
stantially constructed cabinet. 
8
‘‘(ii) Except as provided in clause (i), any security 
9
measures required by the Attorney General for applicants 
10
conducting research with marijuana pursuant to a reg-
11
istration under this paragraph shall be consistent with the 
12
security measures for applicants conducting research on 
13
other controlled substances in schedule II that have a 
14
similar risk of diversion and abuse. 
15
‘‘(F)(i) If the Attorney General grants an application 
16
for registration under this paragraph, the applicant may 
17
amend or supplement the research protocol and proceed 
18
with the research under such amended or supplemented 
19
protocol, without additional review or approval by the At-
20
torney General or the Secretary of Health and Human 
21
Services if the applicant does not change the type of mari-
22
juana, the source of the marijuana, or the conditions 
23
under which the marijuana is stored, tracked, or adminis-
24
tered. 
25
05:02 Oct 26, 2021
H5657
8 
•HR 5657 IH
‘‘(ii) If an applicant amends or supplements the re-
1
search protocol or initiates research on a new research 
2
protocol under clause (i), the applicant shall, in order to 
3
renew the registration under this paragraph, provide no-
4
tice to the Attorney General of the amended or supple-
5
mented research protocol or any new research protocol in 
6
the applicant’s renewal materials. 
7
‘‘(iii)(I) If an applicant amends or supplements a re-
8
search protocol and the amendment or supplement in-
9
volves a change to the type of marijuana, the source of 
10
the marijuana, or conditions under which the marijuana 
11
is stored, tracked, or administered, the applicant shall pro-
12
vide notice to the Attorney General not later than 30 days 
13
before proceeding on such amended or supplemental re-
14
search or new research protocol, as the case may be. 
15
‘‘(II) If the Attorney General does not object during 
16
the 30-day period following a notification under subclause 
17
(I), the applicant may proceed with the amended or sup-
18
plemental research or new research protocol. 
19
‘‘(iv) The Attorney General may object to an amend-
20
ed or supplemental protocol or a new research protocol 
21
under clause (i) or (iii) only if additional security meas-
22
ures are needed to safeguard against diversion or abuse. 
23
‘‘(G) If marijuana is listed on a schedule other than 
24
schedule I, the provisions of paragraphs (1), (2), and (4) 
25
05:02 Oct 26, 2021
H5657
9 
•HR 5657 IH
that apply to research with a controlled substance in the 
1
applicable schedule shall apply to research with marijuana 
2
or that compound, as applicable, in lieu of the provisions 
3
of subparagraphs (A) through (F) of this paragraph. 
4
‘‘(H) Nothing in this paragraph shall be construed 
5
as limiting the authority of the Secretary under section 
6
505(i) of the Federal Food, Drug, and Cosmetic Act or 
7
over requirements related to research protocols, including 
8
changes in— 
9
‘‘(i) the method of administration of marijuana; 
10
‘‘(ii) the dosing of marijuana; and 
11
‘‘(iii) the number of individuals or patients in-
12
volved in research.’’. 
13
SEC. 3. MANUFACTURE AND DISTRIBUTION OF MARIJUANA 
14
FOR USE IN LEGITIMATE RESEARCH. 
15
Section 303 of the Controlled Substances Act (21 
16
U.S.C. 823), as amended by section 2, is further amended 
17
by adding at the end the following: 
18
‘‘(l) REGISTRATION OF PERSONS TO MANUFACTURE 
19
AND DISTRIBUTE MARIJUANA FOR USE IN LEGITIMATE 
20
RESEARCH.— 
21
‘‘(1) REGISTRATION OF MANUFACTURERS.— 
22
‘‘(A) IN
GENERAL.—Beginning not later 
23
than the day that is 1 year after the date of en-
24
actment of the Medical Marijuana Research 
25
05:02 Oct 26, 2021
H5657
10 
•HR 5657 IH
Act, the Attorney General, pursuant to sub-
1
section (f)(3) and subject to subparagraph (B) 
2
of this paragraph, shall register an applicant to 
3
manufacture marijuana (including any deriva-
4
tive, extract, preparation, and compound there-
5
of) that is intended for— 
6
‘‘(i) the ultimate and exclusive use by 
7
qualified marijuana researchers for re-
8
search pursuant to subsection (f)(3); or 
9
‘‘(ii) subsequent downstream manu-
10
facture by a duly registered manufacturer 
11
for the ultimate and exclusive use by quali-
12
fied marijuana researchers for research 
13
pursuant to subsection (f)(3). 
14
‘‘(B) PUBLIC
INTEREST.—The Attorney 
15
General shall register an applicant under sub-
16
paragraph (A) unless the Attorney General de-
17
termines that the issuance of such registration 
18
is inconsistent with the public interest. In deter-
19
mining the public interest, the Attorney General 
20
shall take into consideration— 
21
‘‘(i) maintenance of effective controls 
22
against diversion of marijuana and any 
23
controlled substance compounded there-
24
05:02 Oct 26, 2021
H5657
11 
•HR 5657 IH
from into other than legitimate medical, 
1
scientific, or research channels; 
2
‘‘(ii) compliance with applicable State 
3
and local laws relating to controlled sub-
4
stance misuse and diversion; 
5
‘‘(iii) prior conviction record of the 
6
applicant under Federal or State laws re-
7
lating to the manufacture, distribution, or 
8
dispensing of such substances; and 
9
‘‘(iv) such other conduct which may 
10
threaten the public health and safety. 
11
‘‘(2) REGISTRATION OF DISTRIBUTORS.— 
12
‘‘(A) IN
GENERAL.—Beginning not later 
13
than the day that is 1 year after the date of en-
14
actment of the Medical Marijuana Research 
15
Act, the Attorney General shall register an ap-
16
plicant to distribute marijuana (including any 
17
derivative, extract, preparation, and compound 
18
thereof) that is intended for the ultimate and 
19
exclusive use by qualified marijuana researchers 
20
for research pursuant to subsection (f)(3) or in-
21
tended for subsequent downstream manufacture 
22
by a duly registered manufacturer for use by 
23
qualified marijuana researchers for research 
24
pursuant to such subsection, unless the Attor-
25
05:02 Oct 26, 2021
H5657
12 
•HR 5657 IH
ney General determines that the issuance of 
1
such registration is inconsistent with the public 
2
interest. 
3
‘‘(B) PUBLIC INTEREST.—In determining 
4
the public interest under subparagraph (A), the 
5
Attorney General shall take into consider-
6
ation— 
7
‘‘(i) the factors specified in clauses (i), 
8
(ii), (iii), and (iv) of paragraph (1)(B); and 
9
‘‘(ii) past experience in the distribu-
10
tion of controlled substances, and the exist-
11
ence of effective controls against diversion. 
12
‘‘(3) NO LIMIT ON NUMBER OF MANUFACTUR-
13
ERS
AND
DISTRIBUTORS.—Notwithstanding any 
14
other provision of law, the Attorney General shall 
15
not impose or implement any limit on the number of 
16
persons eligible to be registered to manufacture or 
17
distribute marijuana pursuant to paragraph (1) or 
18
(2). 
19
‘‘(4) REQUIREMENT TO VERIFY USE FOR LE-
20
GITIMATE RESEARCH.—As a condition of registra-
21
tion under this section to manufacture or distribute 
22
marijuana, the Attorney General shall require the 
23
registrant— 
24
05:02 Oct 26, 2021
H5657
13 
•HR 5657 IH
‘‘(A) to require any person to whom the 
1
marijuana will be supplied to submit docu-
2
mentation demonstrating that the marijuana 
3
(including any derivative, extract, preparation, 
4
and compound thereof) will be ultimately used 
5
exclusively by qualified marijuana researchers 
6
for research pursuant to subsection (f)(3) or for 
7
subsequent downstream manufacture by a duly 
8
registered manufacturer for use by qualified 
9
marijuana researchers for research pursuant to 
10
such subsection; 
11
‘‘(B) in the case of distribution, to com-
12
plete, with respect to that distribution, the ap-
13
propriate order form in accordance with section 
14
308 and to upload such forms to the system 
15
used by the Drug Enforcement Administration 
16
for such distribution; 
17
‘‘(C) to include in the labeling of any mari-
18
juana so manufactured or distributed— 
19
‘‘(i) the following statement: ‘This 
20
material is for biomedical and scientific re-
21
search purposes only.’; and 
22
‘‘(ii) the name of the requestor of the 
23
marijuana; 
24
05:02 Oct 26, 2021
H5657
14 
•HR 5657 IH
‘‘(D) to limit the transfer and sale of any 
1
marijuana under this subsection— 
2
‘‘(i) to researchers who are registered 
3
under this Act to conduct research with 
4
marijuana or to manufacturers duly reg-
5
istered under this subsection; and 
6
‘‘(ii) for purposes of use in preclinical 
7
research or in a clinical investigation pur-
8
suant to an investigational new drug ex-
9
emption under 505(i) of the Federal Food, 
10
Drug, and Cosmetic Act or for the pur-
11
poses of further manufacturing of mari-
12
juana; and 
13
‘‘(E) to transfer or sell any marijuana 
14
manufactured under this subsection only with 
15
prior, written consent for the transfer or sale by 
16
the Attorney General. 
17
‘‘(5) TIMING.—Not later than 60 days after re-
18
ceipt of a request for registration under this sub-
19
section to manufacture or distribute marijuana, the 
20
Attorney General shall— 
21
‘‘(A) grant or deny the request; and 
22
‘‘(B) in the case of a denial, provide a 
23
written explanation of the basis for the denial. 
24
05:02 Oct 26, 2021
H5657
15 
•HR 5657 IH
‘‘(6) DEEMED
APPROVAL.—If the Attorney 
1
General fails to grant or deny a request for registra-
2
tion under this subsection to manufacture or dis-
3
tribute marijuana within the 60-day period referred 
4
to in paragraph (5), such request is deemed ap-
5
proved.’’. 
6
SEC. 4. TERMINATION OF INTERDISCIPLINARY REVIEW 
7
PROCESS FOR NON-NIH-FUNDED QUALIFIED 
8
MARIJUANA RESEARCHERS. 
9
The Secretary of Health and Human Services may 
10
not— 
11
(1) reinstate the Public Health Service inter-
12
disciplinary review process described in the guidance 
13
entitled ‘‘Guidance on Procedures for the Provision 
14
of Marijuana for Medical Research’’ (issued on May 
15
21, 1999); or 
16
(2) create an additional review of scientific pro-
17
tocols that is only conducted for research on mari-
18
juana other than the review of research protocols 
19
performed at the request of a qualified marijuana 
20
researcher conducting nonhuman research that is 
21
not federally funded, in accordance with section 
22
303(f)(3)(A) of the Controlled Substances Act, as 
23
added by section 2 of this Act. 
24
05:02 Oct 26, 2021
H5657
16 
•HR 5657 IH
SEC. 5. CONSIDERATION OF RESULTS OF RESEARCH. 
1
Immediately upon the approval by the Food and 
2
Drug Administration of an application for a drug that 
3
contains marijuana (as defined in section 102 of the Con-
4
trolled Substances Act (21 U.S.C. 802), as amended by 
5
section 8 of this Act) under section 505 of the Federal 
6
Food, Drug, and Cosmetic Act (21 U.S.C. 355), and (irre-
7
spective of whether any such approval is granted) not later 
8
than the date that is 5 years after the date of enactment 
9
of this Act, the Secretary of Health and Human Services 
10
shall— 
11
(1) conduct a review of existing medical and 
12
other research with respect to marijuana; 
13
(2) submit a report to the Congress on the re-
14
sults of such review; and 
15
(3) include in such report whether, taking into 
16
consideration the factors listed in section 201(c) of 
17
the Controlled Substances Act (21 U.S.C. 811(c)), 
18
as well as any potential for medical benefits, any 
19
gaps in research, and any impacts of Federal restric-
20
tions and policy on research, marijuana should be 
21
transferred to a schedule other than schedule I (if 
22
marijuana has not been so transferred already). 
23
05:02 Oct 26, 2021
H5657
17 
•HR 5657 IH
SEC. 6. PRODUCTION QUOTAS FOR MARIJUANA GROWN 
1
FOR LEGITIMATE, SCIENTIFIC RESEARCH. 
2
Section 306 of the Controlled Substances Act (21 
3
U.S.C. 826) is amended by adding at the end the fol-
4
lowing: 
5
‘‘(j) The Attorney General may only establish a quota 
6
for production of marijuana that is manufactured and dis-
7
tributed in accordance with the Medical Marijuana Re-
8
search Act that meets the changing medical, scientific, and 
9
industrial needs for marijuana.’’. 
10
SEC. 7. ARTICLE 28 OF THE SINGLE CONVENTION ON NAR-
11
COTIC DRUGS. 
12
Article 28 of the Single Convention on Narcotic 
13
Drugs shall not be construed to prohibit, or impose addi-
14
tional restrictions upon, research involving marijuana, or 
15
the manufacture, distribution, or dispensing of marijuana, 
16
that is conducted in accordance with the Controlled Sub-
17
stances Act (21 U.S.C. 801 et seq.), this Act, and the 
18
amendments made by this Act. 
19
SEC. 8. DEFINITIONS. 
20
(a) QUALIFIED MARIJUANA RESEARCHER.—In this 
21
Act, the term ‘‘qualified marijuana researcher’’ has the 
22
meaning given the term in section 303(f)(3) of the Con-
23
trolled Substances Act, as added by section 2(d) of this 
24
Act. 
25
05:02 Oct 26, 2021
H5657
18 
•HR 5657 IH
(b) UPDATING TERM.—Section 102(16) of the Con-
1
trolled Substances Act (21 U.S.C. 802(16)) is amended— 
2
(1) in subparagraph (A), by striking ‘‘the term 
3
‘marihuana’ means’’ and inserting ‘‘the terms ‘mari-
4
huana’ and ‘marijuana’ mean’’; and 
5
(2) in subparagraph (B), by striking ‘‘The term 
6
‘marihuana’ does not’’ and inserting ‘‘The terms 
7
‘marihuana’ and ‘marijuana’ do not’’. 
8
SEC. 9. DETERMINATION OF BUDGETARY EFFECTS. 
9
The budgetary effects of this Act, for the purpose of 
10
complying with the Statutory Pay-As-You-Go Act of 2010, 
11
shall be determined by reference to the latest statement 
12
titled ‘‘Budgetary Effects of PAYGO Legislation’’ for this 
13
Act, submitted for printing in the Congressional Record 
14
by the Chairman of the House Budget Committee, pro-
15
vided that such statement has been submitted prior to the 
16
vote on passage. 
17
Æ 
05:02 Oct 26, 2021
H5657
